Collagen/β1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner

Molecular Biology of the Cell

Volumn 23, Issue 17, 2012, Pages 3473-3484

  El Azreq, Mohammed Amine ^a   Naci, Dalila ^a   Aoudjit, Fawzi ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; BETA1 INTEGRIN; COLLAGEN; COLLAGEN RECEPTOR; DOXORUBICIN; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA;

ACTIN POLYMERIZATION; APOPTOSIS; ARTICLE; BIOACCUMULATION; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, CD29; APOPTOSIS; CELL LINE, TUMOR; COLLAGEN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JURKAT CELLS; LEUKEMIA, T-CELL; MAP KINASE SIGNALING SYSTEM; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROTEIN TRANSPORT;

EID: 84865750870     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E12-02-0132     Document Type: Article

References (63)

1. Abdul-Ghani R, Serra V, Gyorffy B, Jurchott K, Solf A, Dietel M, Schafer R (2006). The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25, 1743-1752.
2. An Y, Ongkeko WM (2009). ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5, 1529-1542.
3. Angelini A, Ciofani G, Baccante G, Di Febbo C, Carmine DI, Cuccurullo F, Porreca E (2007). Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells. Anticancer Res 27, 351-355.
4. Aoudjit F, Guo W, Gagnon-Houde JV, Castaigne JG, Alcaide-Loridan C, Charron D, Al-Daccak R (2004). HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. Exp Cell Res 299, 79-90.
5. Aoudjit F, Vuori K (2000). Engagement of the alpha2beta1 integrin inhibits Fas ligand expression and activation-induced cell death in T cells in a focal adhesion kinase-dependent manner. Blood 95, 2044-2051.
6. Beedholm-Ebsen R, van de Wetering K, Hardlei T, Nexo E, Borst P, Moestrup SK (2010). Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. Blood 115, 1632-1639.
7. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD (2002). Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62, 6172-6177.
8. Bijian K, Zhang L, Shen SH (2007). Collagen-mediated survival signaling is modulated by CD45 in Jurkat T cells. Mol Immunol 44, 3682-3690.
9. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O (2006). Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20, 95-102.
10. Burkhart CA et al. (2009). Small-molecule multidrug resistance-associated protein 1 inhibitor Reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 69, 6573-6580.
11. Chan BM, Wong JG, Rao A, Hemler ME (1991). T cell receptor-dependent, antigen-specific stimulation of a murine T cell clone induces a transient, VLA protein-mediated binding to extracellular matrix. J Immunol 147, 398-404.
12. Chen ZS, Tiwari AK (2011). Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 278, 3226-3245.
13. Chetoui N, Gendron S, Chamoux E, Aoudjit F (2006). Collagen type I-mediated activation of ERK/MAP kinase is dependent on Ras, Raf-1 and protein phosphatase 2A in Jurkat T cells. Mol Immunol 43, 1687-1693.
14. Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, Miele L, Beck WT (2011). Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci USA 108, 20778-20783.
15. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654.
16. Consoli U et al. (2002). Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 116, 774-780.
17. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, Housset C, Rosmorduc O (2002). Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35, 1010-1021.
18. Deeley RG, Westlake C, Cole SP (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86, 849-899.
19. El Azreq MA, Garceau V, Bourgoin SG (2011). Cytohesin-1 regulates fMLF-mediated activation and functions of the beta2 integrin Mac-1 in human neutrophils. J Leukoc Biol 89, 823-836.
20. Fodale V, Pierobon M, Liotta L, Petricoin E (2011). Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 17, 89-95.
21. Franco R, Cidlowski JA (2006). SLCO/OATP-like transport of glutathione in FasL-induced apoptosis: glutathione efflux is coupled to an organic anion exchange and is necessary for the progression of the execution phase of apoptosis. J Biol Chem 281, 29542-29557.
22. Gendron S, Couture J, Aoudjit F (2003). Integrin alpha2beta1 inhibits Fas-mediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway. J Biol Chem 278, 48633-48643.
23. Gendron S, Couture J, Aoudjit F (2005). Collagen type I signaling reduces the expression and the function of human receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes. Eur J Immunol 35, 3673-3682.
24. Goh F et al. (2009). Selective induction of the Notch ligand Jagged-1 in macrophages by soluble egg antigen from Schistosoma mansoni involves ERK signalling. Immunology 127, 326-337.
25. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK, Katovich MJ (2007). ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) 113, 357-364.
26. Gutmann H, Fricker G, Torok M, Michael S, Beglinger C, Drewe J (1999). Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res 16, 402-407.
27. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J (2005). Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 70, 695-699.
28. Hammond CL, Marchan R, Krance SM, Ballatori N (2007). Glutathione export during apoptosis requires functional multidrug resistance-associated proteins. J Biol Chem 282, 14337-14347.
29. Han L, Wierenga AT, Rozenveld-Geugien M, van de Lande K, Vellenga E, Schuringa JJ (2009). Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS One 4, e7989.
30. Harburger DS, Calderwood DA (2009). Integrin signalling at a glance. J Cell Sci 122, 159-163.
31. Hehlgans S, Haase M, Cordes N (2007). Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775, 163-180.
32. Hummel I, Klappe K, Ercan C, Kok JW (2011). Multidrug resistance-related protein 1 (MRP1) function and localization depend on cortical actin. Mol Pharmacol 79, 229-240.
33. Humphries JD, Byron A, Humphries MJ (2006). Integrin ligands at a glance. J Cell Sci 119, 3901-3903.
34. Ikeda K et al. (1999). Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes. Int J Cancer 82, 599-604.
35. Ivanoff J, Talme T, Sundqvist KG (2005). The role of chemokines and extracellular matrix components in the migration of T lymphocytes into three-dimensional substrata. Immunology 114, 53-62.
36. Kurz EU, Cole SP, Deeley RG (2001). Identification of DNA-protein interactions in the 5′ flanking and 5′ untranslated regions of the human multidrug resistance protein (MRP1) gene: evaluation of a putative antioxidant response element/AP-1 binding site. Biochem Biophys Res Commun 285, 981-990.
37. Lebedeva IV, Pande P, Patton WF (2011). Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. PLoS One 6, e22429.
38. Lee CH (2002). Differential regulation of P-glycoprotein genes in primary rat hepatocytes by collagen sandwich and drugs. J Cell Biochem 86, 12-20.
39. Lee JW, Juliano R (2004). Mitogenic signal transduction by integrin- and growth factor receptor-mediated pathways. Mol Cells 17, 188-202.
40. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA (2006). Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116, 1955-1962.
41. Lotz C, Kelleher DK, Gassner B, Gekle M, Vaupel P, Thews O (2007). Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells. Oncol Rep 17, 239-244.
42. Luqmani YA (2005). Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1), 35-48.
43. Martel J, Payet MD, Dupuis G (1997). The MDR1 (P-glycoprotein) and MRP (P-190) transporters do not play a major role in the intrinsic multiple drug resistance of Jurkat T lymphocytes. Leuk Res 21, 1077-1086.
44. Meads MB, Gatenby RA, Dalton WS (2009). Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9, 665-674.
45. Meads MB, Hazlehurst LA, Dalton WS (2008). The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14, 2519-2526.
46. Merchant JL, Du M, Todisco A (1999). Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem Biophys Res Commun 254, 454-461.
47. Muredda M, Nunoya K, Burtch-Wright RA, Kurz EU, Cole SP, Deeley RG (2003). Cloning and characterization of the murine and rat mrp1 promoter regions. Mol Pharmacol 64, 1259-1269.
48. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK (2000). Role of extra-cellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60, 2497-2503.
49. Noonan KE et al. (1990). Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87, 7160-7164.
50. Poulain S, Lepelley P, Preudhomme C, Cambier N, Cornillon J, Wattel E, Cosson A, Fenaux P (2000). Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. Br J Haematol 110, 591-598.
51. Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH (2004). Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 311, 476-484.
52. Roos PH, Bolt HM (2005). Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin Drug Metab Toxicol 1, 187-202.
53. Ruzza P, Rosato A, Rossi CR, Floreani M, Quintieri L (2009). Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem 9, 763-777.
54. Scharenberg CW, Harkey MA, Torok-Storb B (2002). The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512.
55. Sharom FJ (2011). The P-glycoprotein multidrug transporter. Essays Biochem 50, 161-178.
56. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, Efferth T (2006). ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 12, 4357-4363.
57. Streuli CH (2009). Integrins and cell-fate determination. J Cell Sci 122, 171-177.
58. Thews O, Nowak M, Sauvant C, Gekle M (2011). Hypoxia-induced extracellular acidosis increases p-glycoprotein activity and chemoresistance in tumors in vivo via p38 signaling pathway. Adv Exp Med Biol 701, 115-122.
59. Thews O, Sauvant C, Gekle M (2009). Impact of the metabolic tumor microenvironment on activity and expression of the multidrug resistance-related protein 1 (MRP1). Acta Physiol 195(Suppl 669), O123.
60. Turncliff RZ, Tian X, Brouwer KL (2006). Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes. Biochem Pharmacol 71, 1520-1529.
61. Van de Walle GR, Vanhoorelbeke K, Majer Z, Illyes E, Baert J, Pareyn I, Deckmyn H (2005). Two functional active conformations of the integrin α2β1, depending on activation condition and cell type. J Biol Chem 280, 36873-36882.
62. van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, Schalkwijk CG, Scheffer GL, Scheper RJ, Jansen G (2004). Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis 63, 138-143.
63. Xu C, Shen G, Yuan X, Kim JH, Gopalkrishnan A, Keum YS, Nair S, Kong AN (2006). ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis 27, 437-445.